



For Immediate Release
01.February.2010

For more information, contact
Veronica Palacios at +1.301.214.7624

Cardiocore CEO and VP, Medical Operations to Present at Central Labs West Core Lab Leaders Present Current and Future Trends in Cardiac Testing

Washington, DC and San Francisco, CA— Cardiocore, a premier centralized cardiac testing lab, announced today that its Chief Executive Officer, Jennifer Cotteleer and Vice President of Medical Operations, Polina Voloshko, MD, will present at *Central Labs West* on February 4-5, 2010. This conference will be hosted in San Francisco, California, where Cardiocore maintains a full-service core lab location supporting the local biotech community.

On Thursday, February 4th at 4:00pm (PST), Ms. Cotteleer will lead a roundtable discussion of biotech and pharmaceutical representatives sharing best practices in outsourcing and operations for cardiac and other imaging modalities. All interested conference attendees are invited to participate in this interactive session.

The following morning, at 11:00am (PST), Ms. Cotteleer will present *Cardiac Safety Industry Trends*. Applying her vast experience in cardiac studies and clinical data management, she will help attending conference delegates and speakers envision the future shape of cardiac testing in clinical trials.

Additionally, on Thursday, February 4th at 2:45pm, Dr. Voloshko will present *Cardiac Safety Evaluation for Oncology Compounds*. This session will examine the benefits of both electrocardiographic (ECG) and echocardiographic (ECHO) biomarkers. It will feature a case study demonstrating how a large pharmaceutical company used echocardiography to successfully identify reversible drug-induced cardiomyopathy in cancer patients.

More details about this key industry conference may be accessed through Cardiocore's web site at <http://www.cardiocore.com/news/events>.

About Cardiocore: Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 17 years. Services include centralized electrocardiography (ECG), Holter, echocardiography (ECHO), multigated acquisition scans (MUGA), and consulting services such as protocol development, scientific reporting and statistical analyses. The company is experienced in the design and the implementation of cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company's advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore's U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. www.cardiocore.com